Assessing the Impact of 2-Step Clostridioides difficile Testing at the Healthcare Facility Level
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciad334 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Nicholas A Turner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Clostridioides difficile, Clostridium Infections. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Two-step testing for Clostridioides difficile infection (CDI) aims to improve diagnostic specificity but may also influence reported epidemiology and patterns of treatment. Some providers fear that 2-step testing may result in adverse outcomes if C. difficile is underdiagnosed.
Methods
Our primary objective was to assess the impact of 2-step testing on reported incidence of hospital-onset CDI (HO-CDI). As secondary objectives, we assessed the impact of 2-step testing on C. difficile–specific antibiotic use and colectomy rates as proxies for harm from underdiagnosis or delayed treatment. This longitudinal cohort study included 2 657 324 patient-days across 8 regional hospitals from July 2017 through March 2022. Impact of 2-step testing was assessed by time series analysis with generalized estimating equation regression models.
Results
Two-step testing was associated with a level decrease in HO-CDI incidence (incidence rate ratio, 0.53 [95% confidence interval {CI}, .48–.60]; P < .001), a similar level decrease in utilization rates for oral vancomycin and fidaxomicin (utilization rate ratio, 0.63 [95% CI, .58–.70]; P < .001), and no significant level (rate ratio, 1.16 [95% CI, .93–1.43]; P = .18) or trend (rate ratio, 0.85 [95% CI, .52–1.39]; P = .51) change in emergent colectomy rates.
Conclusions
Two-step testing is associated with decreased reported incidence of HO-CDI, likely by improving diagnostic specificity. The parallel decrease in C. difficile–specific antibiotic use offers indirect reassurance against underdiagnosis of C. difficile infections still requiring treatment by clinician assessment. Similarly, the absence of any significant change in colectomy rates offers indirect reassurance against any rise in fulminant C. difficile requiring surgical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA.
- Duke Center for Antimicrobial Stewardship and Infection Prevention, Duke University Medical Center, Durham, North Carolina.
- Duke Clinical Microbiology Laboratory, Duke University Health System, Durham, North Carolina.
- Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
ORCID-Profile: Nicholas A Turner
Förderung
- NIAID NIH HHS
- National Institutes of Health
Zitieren
APA
Turner, N. A., Krishnan, J., Nelson, A., Polage, C. R., Cochran, R. L., Fike, L., Kuhar, D. T., Kutty, P. K., Snyder, R. L., & Anderson, D. J. (2023). Assessing the Impact of 2-Step Clostridioides difficile Testing at the Healthcare Facility Level. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad334
Vancouver
Turner NA, Krishnan J, Nelson A, Polage CR, Cochran RL, Fike L, et al. Assessing the Impact of 2-Step Clostridioides difficile Testing at the Healthcare Facility Level. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad334
BibTeX
@article{Turner2023,
author = {Turner, Nicholas A and Krishnan, Jay and Nelson, Alicia and Polage, Christopher R and Cochran, Ronda L and Fike, Lucy and Kuhar, David T and Kutty, Preeta K and Snyder, Rachel L and Anderson, Deverick J},
title = {Assessing the Impact of 2-Step Clostridioides difficile Testing at the Healthcare Facility Level},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciad334}
}
EUVIMED